KR20060038396A - New saponin compound, saponin solution containing the same a preparation method thereof, and pharmaceutical compositions, health foods and cosmetics containing the saponin as an active component - Google Patents
New saponin compound, saponin solution containing the same a preparation method thereof, and pharmaceutical compositions, health foods and cosmetics containing the saponin as an active component Download PDFInfo
- Publication number
- KR20060038396A KR20060038396A KR1020057024035A KR20057024035A KR20060038396A KR 20060038396 A KR20060038396 A KR 20060038396A KR 1020057024035 A KR1020057024035 A KR 1020057024035A KR 20057024035 A KR20057024035 A KR 20057024035A KR 20060038396 A KR20060038396 A KR 20060038396A
- Authority
- KR
- South Korea
- Prior art keywords
- saponin
- edible
- group
- ginseng
- weight
- Prior art date
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 110
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 102
- -1 saponin compound Chemical class 0.000 title claims abstract description 37
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 150000007949 saponins Chemical class 0.000 title claims description 79
- 238000002360 preparation method Methods 0.000 title claims description 31
- 235000013402 health food Nutrition 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 9
- 230000014616 translation Effects 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 claims abstract description 8
- 201000004647 tinea pedis Diseases 0.000 claims abstract description 8
- 206010019133 Hangover Diseases 0.000 claims abstract description 7
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 6
- 230000017531 blood circulation Effects 0.000 claims abstract description 6
- 201000009890 sinusitis Diseases 0.000 claims abstract description 6
- 208000017520 skin disease Diseases 0.000 claims abstract description 6
- 238000001784 detoxification Methods 0.000 claims abstract description 5
- 230000003908 liver function Effects 0.000 claims abstract description 5
- 238000011084 recovery Methods 0.000 claims abstract description 5
- 238000001356 surgical procedure Methods 0.000 claims abstract 3
- 235000017709 saponins Nutrition 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 79
- 240000004371 Panax ginseng Species 0.000 claims description 47
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 47
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 47
- 235000008434 ginseng Nutrition 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 150000007524 organic acids Chemical group 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 235000012907 honey Nutrition 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 150000002016 disaccharides Chemical class 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 8
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 8
- 244000082204 Phyllostachys viridis Species 0.000 claims description 8
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 8
- 239000011425 bamboo Chemical class 0.000 claims description 8
- 239000007809 chemical reaction catalyst Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940010454 licorice Drugs 0.000 claims description 7
- 235000021419 vinegar Nutrition 0.000 claims description 7
- 239000000052 vinegar Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 235000011511 Diospyros Nutrition 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007259 addition reaction Methods 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 235000021329 brown rice Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108020004707 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 240000000425 Chaenomeles speciosa Species 0.000 claims description 3
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims description 3
- 208000034656 Contusions Diseases 0.000 claims description 3
- 244000236655 Diospyros kaki Species 0.000 claims description 3
- 241000402754 Erythranthe moschata Species 0.000 claims description 3
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 claims description 3
- 210000003056 antler Anatomy 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 235000021422 persimmon vinegar Nutrition 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000037911 visceral disease Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical group COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 2
- 241000209020 Cornus Species 0.000 claims description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- 239000006000 Garlic extract Substances 0.000 claims description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 240000007890 Leonurus cardiaca Species 0.000 claims description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 241000241413 Propolis Species 0.000 claims description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- 240000006079 Schisandra chinensis Species 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 229910052571 earthenware Inorganic materials 0.000 claims description 2
- 239000008157 edible vegetable oil Substances 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000020706 garlic extract Nutrition 0.000 claims description 2
- 229910052732 germanium Inorganic materials 0.000 claims description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 235000014593 oils and fats Nutrition 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229940069949 propolis Drugs 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 229940109850 royal jelly Drugs 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 125000005457 triglyceride group Chemical group 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 206010049153 Allergic sinusitis Diseases 0.000 claims 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims 1
- 240000006891 Artemisia vulgaris Species 0.000 claims 1
- 235000002568 Capsicum frutescens Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 244000126002 Ziziphus vulgaris Species 0.000 claims 1
- 239000002274 desiccant Substances 0.000 claims 1
- 235000018927 edible plant Nutrition 0.000 claims 1
- 230000002431 foraging effect Effects 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000007177 brain activity Effects 0.000 abstract description 3
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 13
- 235000002789 Panax ginseng Nutrition 0.000 description 10
- 206010016256 fatigue Diseases 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000003716 rejuvenation Effects 0.000 description 6
- 240000008866 Ziziphus nummularia Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000017788 Cydonia oblonga Nutrition 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000010686 shark liver oil Substances 0.000 description 3
- 229940069764 shark liver oil Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 244000280244 Luffa acutangula Species 0.000 description 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000005470 impregnation Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000021425 apple cider vinegar Nutrition 0.000 description 1
- 229940088447 apple cider vinegar Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
본 발명은 신규한 구조를 갖는 사포닌 화합물 및 그의 제조방법에 관한 것이며, 또한, 이 사포닌 화합물을 활성성분으로 함유하는 약제학적 조성물, 기능성 식품 또는 화장품에 관한 것이다. 본 발명에 따른 약제학적 조성물 및 기능성 식품은 면역증강, 체력증강, 간기능 보호 및 숙취해독, 단백질 생성 촉진, 두뇌활동 촉진 및 집중력 향상 및 수술 후 회복증강 작용을 할뿐 아니라, 당뇨병, 혈액순환장해, 우울증, 피부질환, 무좀, 습진, 알레르기 비염, 축농증 등의 질환의 예방 또는 치료 효과를 갖는다.The present invention relates to a saponin compound having a novel structure and a method for producing the same, and also to a pharmaceutical composition, a functional food or a cosmetic containing the saponin compound as an active ingredient. The pharmaceutical composition and the functional food according to the present invention not only act on immune enhancement, physical strength, liver function protection and hangover detoxification, protein production, promotion of brain activity and improvement of concentration and recovery after surgery, diabetes, blood circulation disorder It has a prophylactic or therapeutic effect on diseases such as depression, skin disease, athlete's foot, eczema, allergic rhinitis, sinusitis.
Description
본 발명은 신규한 사포닌 화합물, 그것을 함유하는 사포닌 조성액 및 그 제조방법, 및 이 사포닌 화합물 또는 조성액을 활성성분으로서 포함하는 약제학적 조성물, 기능성 식품 또는 화장품에 관한 것이다.The present invention relates to a novel saponin compound, a saponin composition containing the same, a method for producing the same, and a pharmaceutical composition, a functional food or a cosmetic comprising the saponin compound or the composition as an active ingredient.
인삼은 예로부터 대표적인 자양 강장제로 널리 사용되고 있는 식물로서, 지금까지 인삼의 성분과 약효에 대한 많은 연구결과가 보고되어 있다. 현재까지 알려진 인삼의 약효로서, 노화억제, 항동맥경화 및 고지혈증 개선, 간기증 항진, 방사선 장해 제거, 면역증강 항혈전, 뇌기능항진, 항스트레스, 혈당강하, 혈압강하 또는 항암작용 등이 알려져 있다.Ginseng is a plant that has been widely used as a representative nutrient tonic since ancient times, and many studies on the components and efficacy of ginseng have been reported so far. Ginseng known to date, anti-aging, anti-arteriosclerosis and hyperlipidemia improvement, hepatic hyperlipidemia, elimination of radiation disorders, immunopotentiation antithrombotic, cerebral hyperactivity, antistress, hypoglycemic, hypotensive or anticancer action is known .
특히, 이와 같은 효과에 대한 연구는 인삼의 약효를 주로 나타낸다고 알려진 다량의 사포닌을 중심으로 하여 이루어지고 있다.In particular, studies on such effects have been carried out around a large amount of saponins known to mainly represent the efficacy of ginseng.
인삼의 사포닌 성분은 화학 구조에 따라 크게 세가지 군으로 나누어진다. 즉 , Protopanaxadiol(PD), Protopanaxatriol(PT), Oleanolic acid이다. 식물계에 존재하는 사포닌은 oleanane 계이고, 인삼 사포닌은 타 식물계에 존재하지 않는 dammarane 계열의 triterpenoid 사포닌으로 알려져 있다. 인삼의 사포닌은 타 식물에서 발견되는 사포닌과는 화학구조가 전혀 다르므로, 타 식물계의 사포닌과 구별하기 위해 인삼(Ginseng) 배당체(Glycoside)란 의미로 '진세노사이드 (Ginsenoside)'라고 부른다.The saponin component of ginseng is divided into three groups according to its chemical structure. That is, Protopanaxadiol (PD), Protopanaxatriol (PT) and Oleanolic acid. Saponins present in the plant family are oleanane family, and ginseng saponins are known as dammarane family triterpenoid saponins that do not exist in other plant systems. Ginseng saponins are completely different from the saponins found in other plants, so they are called 'Ginsenoside' in the sense of Ginseng glycosides to distinguish them from other plant saponins.
지금까지의 연구결과에 따르면, 인삼에 다량 함유되어 있는 사포닌의 구조는 90% 이상이 담마렌계 트리 테르페노이드 디올, 트리올로 되어 있으며, 더욱 자세히 살펴보면, 벤젠고리 3개와 오원고리 및 당기(글리콘)와 450종류 이상의 비당기(아그리콘)로 구성되어 있다.According to the research results so far, more than 90% of the structure of saponin contained in ginseng is made of dhammarene-based triterpenoid diols and triols, and more specifically, three benzene rings, five-membered rings and pulled ( Glycone) and more than 450 kinds of non-sugar (aglycone).
인삼중에서 특이 성분을 증가시켜 인삼의 약효를 증대 시킬 수 있는 방법이 연구되어 왔으며, 이를 위해 인삼의 가공방법과 그에 따른 생리활성 및 생리활성 물질의 변화에 대한 연구가 수행되어 왔다. 즉, 인삼을 가공하여 기존의 수삼, 백삼 및 홍삼보다 약효가 증강된 가공인삼을 제조하였고, 이 가공인삼에 존재하는 각종 성분들을 분리하여 약효를 검증하는 것이 진행되어 왔으며, 이 과정에서, 원래의 인삼에는 존재하지 않는 신규한 사포닌 성분들이 발견되었다.Increasing the specific components of ginseng has been studied how to increase the efficacy of ginseng, and for this purpose, a study on the processing method of ginseng and the changes in its bioactive and bioactive substances have been studied. In other words, by processing ginseng to produce a processed ginseng with enhanced efficacy than conventional ginseng, white ginseng and red ginseng, and to verify the efficacy by separating the various components present in the processed ginseng, in the process, A new saponin component was found that does not exist in ginseng.
홍삼에 존재하는 사포닌 Rh1, Rh2, Rg2, Rg3 등은 수삼이나 백삼 등에는 거의 존재하지 않으나(일본 약학잡지, 1993), 홍삼에는 월등히 많이 존재한다고 알려져 있다.Saponins Rh1, Rh2, Rg2, and Rg3 present in red ginseng are rarely present in fresh ginseng or white ginseng (Japanese Pharmacy Magazine, 1993), but are known to be present in red ginseng.
본 발명자는 진세노사이드 성분들에 대해 더욱 연구한 결과, 종래의 사포닌 화합물과는 상이한 구조를 갖는 사포닌 화합물 ('Rxn'라 칭함, n은 1∼100의 정수로, 100가지 정도의 다양한 구조를 가질 수 있다는 것을 의미함)을 얻을 수 있었고, 상기 신규한 사포닌 화합물(들)을 포함하는 사포닌 조성액이 종래의 사포닌 조성물이 갖는 약리효과를 가질 뿐만 아니라, 그 외에도 피부습진, 모좀, 알러지성 피부염, 아토피성 피부염, 눈, 코, 입, 혀, 목구멍 등의 여러 질환 치료에는 훨씬 탁월한 효과를 나타냄을 발견하여 본 발명을 완성하기에 이르렀다.As a result of further studies on ginsenoside components, the present inventors have found that saponin compounds having different structures from conventional saponin compounds (called 'Rxn', n is an integer of 1 to 100, and various kinds of structures of about 100 Saponin composition containing the novel saponin compound (s) not only has the pharmacological effect of the conventional saponin composition, but also skin eczema, hairsome, allergic dermatitis, The present invention has been found to have a far superior effect in the treatment of various diseases such as atopic dermatitis, eyes, nose, mouth, tongue, throat, and the like.
도 1은 본 발명의 조성물의 HPLC 분석결과를 나타내는 스펙트럼이다.1 is a spectrum showing the results of HPLC analysis of the composition of the present invention.
도 2는 금산인삼조합의 조성물의 HPLC 분석결과를 나타내는 스펙트럼이다.Figure 2 is a spectrum showing the HPLC analysis of the composition of Geumsan ginseng combination.
도 3은 정관장 제품의 HPLC 분석결과를 나타내는 스펙트럼이다.3 is a spectrum showing the results of HPLC analysis of Jeonggwanjang products.
기술적 과제Technical challenges
본 발명의 목적은 신규한 사포닌 화합물, 이것을 함유하는 사포닌 조성액 및 그 제조방법을 제공하는 것이다.An object of the present invention is to provide a novel saponin compound, a saponin composition containing the same, and a method for producing the same.
본 발명의 또 다른 목적은 상기 신규한 화합물 또는 이것을 함유하는 사포닌 조성액을 활성성분으로 포함하는 약제학적 조성물 및 기능성 식품을 제공하는 것이다.Still another object of the present invention is to provide a pharmaceutical composition and a functional food comprising the novel compound or a saponin composition containing the same as an active ingredient.
또한, 본 발명의 목적은 상기 신규한 화합물 또는 이것을 함유하는 사포닌 조성액을 활성성분으로 포함하는 화장품을 제공하는 것이다.It is also an object of the present invention to provide a cosmetic comprising the novel compound or a saponin composition containing the same as an active ingredient.
발명의 실시를 위한 형태Embodiment for Invention
본 발명의 목적에 따라서, 하기식 Ⅰ의 구조를 갖는 신규한 사포닌 화합물이 제공된다:According to the object of the present invention there is provided a novel saponin compound having the structure of formula I:
상기 식에서, 1∼25는 기존 사포닌 기본골격 탄소의 번호를 말하며, R26 ∼R29 및 R'4, R'9, 및 R'10 기는 단당류, 이당류, 올리고당류, 다당류들인 글리콘이거나 수소원자이고, 상기 육환고리 또는 오환고리의 이중결합이 있는 탄소[C]에도 임의로 단당류, 이당류, 올리고당류, 다당류들인 글리콘이 결합될 수 있고, 상기 R26 ∼ R29 및 R'4, R'9 및 R'10 기 또는 육환고리와 오환고리의 이중결합이 있는 탄소 중 하나 이상에는 하기로 이루어진 군으로부터 선택되는 하나 이상의 기가 사포닌 기본 골격과 부가반응 될 수 있다 :Wherein 1 to 25 refers to a number of existing basic skeleton saponin carbon, R 26 ~R 29 and R '4, R' 9, and R '10 groups are monosaccharides, disaccharides, oligosaccharides, polysaccharides, which are a hydrogen atom glycolate In addition, the hexacyclic ring or cyclic ring of carbon [C] having a double bond may optionally be a monosaccharide, a disaccharide, an oligosaccharide, a glycopolysaccharides of polysaccharides may be bonded, the R 26 to R 29 and R ' 4 , R' 9 And at least one of R ′ 10 groups or a carbon having a double bond of a hexacyclic ring and a cyclic ring, at least one group selected from the group consisting of:
식용 유기산에 함유된 카르복실기가 1∼20개인 유기산군;An organic acid group having 1 to 20 carboxyl groups contained in an edible organic acid;
식용 프로폴리스에 함유된 페닐기 3개의 기본 골격을 갖는 프라보노이드 군;A group of pravonoids having a basic skeleton of three phenyl groups contained in edible propolis;
식용 유지에 함유된 탄소수 9개 이상의 불포화도 1급, 2급 또는 3급의 트리글리세라이드 군;Triglyceride group having 9 or more unsaturation primary, secondary or tertiary carbon atoms contained in edible oils and fats;
식용 알코올로서 탄소수 3개 이상의 알코올 군;Alcohol group having 3 or more carbon atoms as an edible alcohol;
식용 동식물 단백질에 함유되어 있는 아미노산과 핵산이 각각 1 또는 합하여 2 이상 ∼ 20개 미만인 아미노산 또는 핵산 군;A group of amino acids or nucleic acids in which two or more amino acids and nucleic acids contained in an edible animal or vegetable protein are each 1 or more in combination;
식용 동식물에 함유되어 있는 스테로이드계 군;Steroid-based groups contained in edible animals and plants;
식용 무기물질인 금, 은, 백금, 나트륨, 칼슘, 아연, 철, 동, 칼륨, 황, 마그네슘, 바륨, 알루미늄, 탄소, 규소, 게르마늄, 인, 세레늄 등이 1 또는 2개 이상인 군.Groups of edible inorganic substances such as gold, silver, platinum, sodium, calcium, zinc, iron, copper, potassium, sulfur, magnesium, barium, aluminum, carbon, silicon, germanium, phosphorus, and selenium.
상기 부가 반응이 일어나는 위치에 따라, 본 발명의 신규한 사포닌 화합물은 다양한 구조를 갖는다.Depending on the location of the addition reaction, the novel saponin compounds of the present invention have a variety of structures.
상기 신규한 사포닌 화합물 또는 이것을 함유하는 사포닌 조성액은 다음의 방법에 의해 제조된다.The novel saponin compound or saponin composition containing the same is produced by the following method.
상기식(Ⅰ)은 간단히, 본 발명자의 일통(一通, Onewholeness Theory)이론으로 설명되며 필요 시에 자료로 제출할 수 있다.Equation (I) is briefly explained by the present inventor's Onewholeness Theory theory and can be submitted as data if necessary.
1) 전처리 단계1) Pretreatment Step
감주, 또는 직전 사포닌 조성액의 제조과정의 잔여액 (사포닌 조성물을 분리한 후 남은 잔유물을 파쇄하여 압출한 액)에, 인삼을 10분 내지 1시간동안 침윤시켰다가 꺼낸다. 이 인삼을 밀폐된 용기에서, 건삼, 줄기 및 잎일 경우는 40 내지 60℃에서 7 ∼ 21일 동안, 수삼일 경우는 20 ∼ 50℃에서 1 ~ 7일 동안 숙성시킨다.Ginseng was infiltrated for 10 minutes to 1 hour and then taken out in the remaining solution of the sake (or saponin composition) solution of the saponin composition. The ginseng is aged in a closed container for 7 to 21 days at 40 to 60 ℃ for dried ginseng, stems and leaves, and 1 to 7 days at 20 to 50 ℃ for fresh ginseng.
이와 같이 속성시킴에 의해 인삼의 가장 외피의 알칼로이드계 물질들의 변성을 유도할 수 있다.In this way, it is possible to induce degeneration of alkaloid-based substances of the outermost skin of ginseng.
2) 당부가 단계2) step by step
상기 전처리된 인삼을 당류,식용 유기산 건약제, 식용염, 반응촉매 및 물과, 또한 기호에 따라서 식용 감미 건약제와 함께 환류장치가 부착된 추출반응기에 선별적으로 투입하고, 상압 하에서 온도 120℃이하에서 20시간 이상 반응시켜 추출한 후, 인삼 등의 투입물을 제거(여과)하고 감압 하에 추출액의 수분을 증발시켜 투여된 물의 양 정도가 되게 하여, 당부가 반응에 의해 글리콘 라디칼이 2개 이상 부가된 화학식 Ⅰ의 사포닌 화합물들을 포함하는 사포닌 조성 액이 제조된다,The pretreated ginseng is selectively added to an extracting reactor equipped with a reflux device together with sugars, edible organic acid medicinal agents, edible salts, reaction catalysts and water, and also edible sweetener medicinal agents according to the preference, and the temperature is 120 ° C. under normal pressure. After extracting by reacting for 20 hours or more below, the inputs such as ginseng are removed (filtered), and the water of the extract is evaporated under reduced pressure to be about the amount of water administered, and two or more glycon radicals are added by the sugar addition reaction. A saponin composition liquid is prepared comprising saponin compounds of formula (I),
상기 전처리된 인삼은 총 물의 양을 기준으로 1∼30 중량%, 바람직하기는 5∼21 중량%가 사용된다.The pretreated ginseng is 1 to 30% by weight, preferably 5 to 21% by weight based on the total amount of water.
본 발명에서 사용가능한 당류는 벌꿀, 단당류, 이당류, 올리고당류, 다당류로 이루어진 군으로부터 선택되는 하나 또는 2이상의 혼합물이며, 1∼20 중량%, 바람직하기는 1.5 ∼ 15 중량%가 사용된다.The sugars usable in the present invention are one, or a mixture of two or more selected from the group consisting of honey, monosaccharides, disaccharides, oligosaccharides, polysaccharides, 1 to 20% by weight, preferably 1.5 to 15% by weight.
상기 다당류로는 플루란, 아밀로스 크실로 글루칸, 아밀로펙틴, 덱스트란, 사이클로덱스트린, 만난, 히드록시에틸 덱스트란, 이눌린, 키틴, 키토산, 수용성 셀룰로스 등이 선택된다.The polysaccharide is selected from flulan, amylose xyloglucan, amylopectin, dextran, cyclodextrin, mannan, hydroxyethyl dextran, inulin, chitin, chitosan, water-soluble cellulose, and the like.
본 발명에서 사용가능한 식용염은 천일염, 죽염, 광염, 볶은 소금으로 이루어지는 군에서 선택되는 하나 또는 2 이상의 혼합물이며, 0.05 ∼ 2 중량%, 바람직하기는 0.1 ∼ 1 중량%가 사용된다.The edible salt usable in the present invention is one or a mixture of two or more selected from the group consisting of sun salt, bamboo salt, light salt and roasted salt, and 0.05 to 2% by weight, preferably 0.1 to 1% by weight is used.
본 발명에서 사용가능한 반응촉매는 백금, 금, 은, 아연, 구리, 셀레늄, 맥반석으로 이루어진 군에서 선택되는 하나 또는 2 이상의 혼합물이며, 0.05 ∼ 2 중량%, 바람직하기는 0.1 ∼ 1 중량%이 사용된다.The reaction catalyst usable in the present invention is one or two or more mixtures selected from the group consisting of platinum, gold, silver, zinc, copper, selenium and elvan, and 0.05 to 2% by weight, preferably 0.1 to 1% by weight. do.
본 발명에서 사용가능한 식용 유기산 건약제는 개미산, 구연산, 호박산, 사과산, 초산, 백반, 매실, 모과, 인진쑥, 익모초, 마늘 엑스, 각종 감식초, 현미식초 등으로 이루어진 군에서 선택되는 하나 또는 2 이상의 혼합물이며, 0.1 ∼ 3중량%, 바람직하기는 0.3 ~ 2 중량%가 사용된다.Edible organic acid medicinal agent usable in the present invention is one or two or more mixtures selected from the group consisting of formic acid, citric acid, succinic acid, malic acid, acetic acid, alum, plum, Chinese quince, jinjin, motherwort, garlic extract, various persimmon vinegar, brown rice vinegar, etc. 0.1-3 weight%, Preferably 0.3-2 weight% is used.
또한, 본 발명에서 사용가능한 식용 감미 건약제는 꿀, 로얄젤리, 각종 단당류, 올리고당 등 이당류, 흑설탕, 대추, 감초, 건포도, 곳감, 칡뿌리, 오미자, 복분자, 산수유, 구기자, 토사자, 자황, 복령 등, 또는 우황, 사향, 녹각가루, 녹용, 웅담, 돈담 및 각종 버섯류로 이루어진 식용 단백질류로 이루어지는 군에서 선택되는 하나 또는 2 이상의 혼합물이며, 0.1 ∼3 중량%, 바람직하기는 0.3 ∼ 2 중량%이 사용된다.In addition, the edible sweetener can be used in the present invention, such as honey, royal jelly, various monosaccharides, oligosaccharides, disaccharides, brown sugar, jujube, licorice, raisins, persimmon, root roots, Schisandra chinensis, bokbunja, cornus, gojija, earthenware, sulphur, Bokryong Or the like, or a mixture of one or two or more selected from the group consisting of edible protein consisting of sulfur, musk, green powder, antler, ungdam, dondam and various mushrooms, and 0.1 to 3% by weight, preferably 0.3 to 2% by weight. This is used.
이 단계에서, 인삼에 존재하던 기존의 사포닌 화합물들 중 총 사포닌 양을 기준으로 1중량% 이상이 당부가 반응에 의해 화학식 Ⅰ의 신규한 사포닌 화합물로 전환된다.In this step, at least 1% by weight based on the total amount of saponin among the existing saponin compounds present in ginseng is converted to the novel saponin compound of formula (I) by a sugar addition reaction.
3) 정제 및 분리 단계3) Purification and Separation Steps
상기에서 제조된 사포닌 조성물을 크로마토그래피, 유기용매 추출 등과 같은 통상의 방법에 의해 정제 및 단리하여 순수한 화학식 Ⅰ의 화합물을 단리할 수 있다.The saponin composition prepared above can be purified and isolated by conventional methods such as chromatography, organic solvent extraction and the like to isolate pure compounds of formula (I).
본 발명의 또 다른 목적에 따라서, 신규한 화학식 Ⅰ의 사포닌 화합물 또는 이것을 함유하는 사포닌 조성액을 활성성분으로 포함하는 약제학적 조성물 및 기능성 식품이 제공된다.According to another object of the present invention, there is provided a pharmaceutical composition and a functional food comprising a novel saponin compound of formula (I) or a saponin composition containing the same as an active ingredient.
본 발명에 따른 약제학적 조성물 및 기능성 식품은 면역증강, 체력증강, 간기능 보호 및 숙취해독, 단백질 생성 촉진, 두뇌활동 촉진 및 집중력 향상 및 수술후 회복증강 작용을 할뿐 아니라, 당뇨병, 혈액순환장해, 우울증, 피부질환, 무좀, 습진, 알레르기 비염, 축농증, 타박상, 화상, 출현성 내장질환 등의 치료예방에 탁월한 단백질 생성 촉진, 뇌, 골수, 기타 내외피부의 단백질 재생 복원 등의 질환의 예방 또는 치료 효과를 갖는다. 특히, 본 발명의 약제학적 조성물 및 기능성 식품은 피부습진, 무좀, 알러지성 피부염, 아토피성 피부염 등의 피부질환 및 눈,코, 입, 혀, 목구멍 등의 여러 질환의 치료 또는 예방에 탁월한 효과를 가진다.The pharmaceutical composition and functional food according to the present invention not only acts as an immune booster, physical strength enhancer, liver function protection and hangover detoxification, protein production, brain activity promotion and concentration enhancement and postoperative recovery, as well as diabetes, blood circulation disorder, Prevent or treat diseases such as depression, skin diseases, athlete's foot, eczema, allergic rhinitis, sinusitis, bruises, burns, and emergent visceral diseases. Has an effect. In particular, the pharmaceutical composition and the functional food of the present invention have an excellent effect in the treatment or prevention of skin diseases such as skin eczema, athlete's foot, allergic dermatitis, atopic dermatitis and various diseases such as eyes, nose, mouth, tongue, throat, etc. Have
상기 약제학적 조성물 및 기능성 식품에서 본 발명에 따른 신규한 사포닌 화함물은 0.01 중량% 이상 함유되는 것이 바람직하다.In the pharmaceutical composition and the functional food, it is preferable that the novel saponin compound according to the present invention is contained by 0.01% by weight or more.
본 발명의 약제학적 조성물은 다양한 경구, 비경구 투여 및 외용제 형태로 제형화 할 수 있다. 즉, 본 발명의 약제학적 조성물은 약제학적 분야에서 통상적으로 사용하는 담체와 함께 배합하여, 정제, 캅셀제, 액제, 현탁제 등의 경구용 제제, 주사용 용액, 또는 현탁액, 또는 연고제, 크림제, 액제 등의 국소형 제제, 좌제 등의 다양한 제제로 제형화 시킬 수 있다.The pharmaceutical compositions of the present invention can be formulated in a variety of oral, parenteral and external application forms. That is, the pharmaceutical composition of the present invention is combined with a carrier commonly used in the pharmaceutical field, oral preparations such as tablets, capsules, solutions, suspensions, injectable solutions, or suspensions, ointments, creams, It may be formulated into a variety of preparations, such as topical preparations such as liquids, suppositories.
본 발명의 조성물과 배합하기 위해 사용되는 담체는 약제학적 분야에서 통상적으로 사용되는 것으로서, 예를 들면, 경구투여용 제제의 경우, 결합제, 활탁제, 붕해제, 부형제 가용화제, 분산제, 안정화제, 현탁화제, 색소, 향료 등이 있으며, 주사제의 경우에는 보존제, 무통화제, 가용화제, 안정화제 등이 있고, 국소 투여용 제제의 경우에는 기제, 부형제, 윤활제, 보존제 등이 있다. 이와 같이 제조된 약제학적 제제는 경구 또는 비경구적으로 투여될 수 있다. 또한, 경구투여시에 약제가 위산에 분해되는 것을 방지하기 위해 제사제를 병용하거나, 정제 등의 경구투여용 고형제제를 장용피로 피복된 제제로 제형화하여 투여할 수 있다.Carriers used in combination with the compositions of the present invention are conventionally used in the pharmaceutical field, for example, in the case of oral preparations, binders, suspending agents, disintegrants, excipient solubilizers, dispersants, stabilizers, Suspending agents, pigments, fragrances, and the like, in the case of injections, there are preservatives, analgesics, solubilizers, stabilizers and the like, and in the case of topical administration, there are bases, excipients, lubricants, preservatives and the like. Pharmaceutical preparations thus prepared may be administered orally or parenterally. In addition, in order to prevent the decomposition of the drug in gastric acid during oral administration, a medicament may be used in combination, or a solid dosage form for oral administration such as tablets may be formulated into a formulation coated with enteric skin.
본 발명의 조성물의 투여량은 제제에 따라 다르며, 인체에 대한 투여량은 체내에서의 활성성분의 흡수도, 불활성화율 및 배설속도, 환자의 연령, 성별 및 병태 등에 따라 적절히 선택될 수 있으며, 일반적으로 성인 기준으로, 본 발명의 사포닌 화합물은 10 ∼ 30mg을 1일 1 ∼ 3회, 본 발명의 사포닌 조성액은 1일에 20 ∼ 30 cc을 1 ∼ 3회 정도 투여되도록 한다.The dosage of the composition of the present invention varies depending on the formulation, and the dosage to the human body may be appropriately selected according to the absorbency, inactivation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, and the like. As an adult, the saponin compound of the present invention is administered 10 to 30 mg 1 to 3 times a day, the saponin composition of the present invention is to be administered about 20 to 30 cc 1 to 3 times a day.
본 발명의 또 다른 목적에 따라서, 본 발명의 신규한 사포닌 화합물 또는 사포닌 조성액을 활성성분으로 포함하는 화장품이 제공된다.According to another object of the present invention, there is provided a cosmetic comprising the novel saponin compound or saponin composition of the present invention as an active ingredient.
본 발명의 화장품에는 활성성분이 신규한 사포닌 조성액일 경우, 총 중량의 30 ∼ 90 중량%로 포함되는 것이 바람직하다. 또한 본 발명의 화장품에는 식용 에틸알콜 5 ∼ 25 중량%, 오이, 수세미외, 알로에, 선인장류 등의 식용 야채류 추출물 및 송이버섯, 느타리버섯, 싸리버섯, 팽이버섯, 상황버섯, 영지버섯, 표고버섯, 동충하초, 당귀, 지황, 백복령, 우황, 사향, 녹각가루, 녹용, 웅담, 돈담 등으로 이루어지는 군에서 선택되는 하나 이상의 혼합물의 한약제 추출물 0.5 ∼ 5 중량%, 꿀벌의 집 왁스, 파라핀 오일, 심해상어간유, 캐비어 등과 유화제, 팩틴류 등으로 이루어지는 군에서 선택되는 하나 이상의 통상의 첨가제 0.1 ∼ 50 중량%, 바람직하기는 0.5 ∼ 35 중량%를 포함할 수 있다.When the active ingredient is a novel saponin composition liquid, the cosmetic of the present invention is preferably included in 30 to 90% by weight of the total weight. In addition, the cosmetics of the present invention, edible ethyl alcohol 5-25% by weight, edible vegetable extracts such as cucumber, loofah, aloe, cactus and matsutake mushroom, oyster mushroom, mori mushroom, enoki mushroom, situation mushroom, ganoderma lucidum mushroom, shiitake mushroom, Cordyceps sinensis 0.5 ~ 5% by weight of herbal extracts of one or more mixtures selected from the group consisting of Angelica, Angelica, Baekhwang, Baekbokryeong, Wuhang, musk, green powder, antler, ungdam, and dondam, Bee house wax, paraffin oil, deep sea shark liver oil, 0.1 to 50% by weight, preferably 0.5 to 35% by weight, of one or more conventional additives selected from the group consisting of caviar and the like, emulsifiers, factins, and the like.
본 발명의 화장품은 통상의 방법에 따라 스킨, 로션, 크림 등의 형태로 제조될 수 있다. 또한, 본 발명의 화장품은 피부세정제, 모발보호제, 목욕용품, 색조화장료, 기초화장료인 것을 특징으로 한다.Cosmetics of the present invention can be prepared in the form of a skin, lotion, cream or the like according to conventional methods. In addition, the cosmetic of the present invention is characterized in that the skin cleaner, hair protector, bath products, color cosmetics, basic cosmetics.
본 발명은 이하의 제조예, 실시예 및 임상예에 의해 더욱 상세히 설명되나, 본 발명이 이것으로 제한되는 것은 아니다.The present invention is described in more detail by the following Preparation Examples, Examples and Clinical Examples, but the present invention is not limited thereto.
제조예 1: 사포닌 조성액Preparation Example 1: Saponin Composition
직전 사포닌 조성액의 제조과정으로부터의 잔여액에 60분 함침한 후 꺼내어 1일 동안 25℃의 온도에서 숙성하여 전처리한 인삼 300g을, 벌꿀 200g, 감초, 지황, 갈근, 곳감으로 이루어진 혼합물의 추출물인 식용 감미건약제 20g, 사과식초, 감식초, 구연산, 매실, 모과, 구연산의 혼합물인 식용 유기산 건약제 20g, 죽염 3g, 반응형 촉매로서 펠렛 상태의 은 3g 및 물 3000g과 함께 환류장치가 부착된 추출 반응기에 선별적으로, 즉 반응형 촉매는 추출반응기 하부에, 당류와 죽염, 유기산은 물에 용해시켜서, 인삼과 건약제는 추출반응기 상부에 투입하고, 상압하에서 약 120℃에서 40시간 동안 반응시켜 추출한 후, 인삼 등 고형물들을 여과하여 제거하고, 추출액이 3000g이하가 되도록 감압하에 수분을 증발시켜 화학식 I의 사포닌 화합물들을 포함하는 사포닌 조성 액을 얻었다.Edible, which is an extract of a mixture consisting of 200 g of honey, licorice, lichens, brown roots, and persimmons, 300 g of ginseng, which has been impregnated with the remaining solution from the preparation of the saponin composition solution for 60 minutes and then taken out and aged at a temperature of 25 ° C. for 1 day. Extraction reactor with reflux device with 20g sweetener, 20g apple cider vinegar, persimmon vinegar, citric acid, plum, Chinese quince, citric acid 20g edible organic acid dry matter, 3g bamboo salt, 3g silver in pellet form as reaction catalyst and 3000g water Selectively, that is, the reactive catalyst is dissolved in the lower part of the extraction reactor, sugars, bamboo salt, and organic acid in water, and ginseng and the medicinal agent are put in the upper part of the extraction reactor, and reacted for about 40 hours at 120 ° C. under normal pressure. After that, the solids such as ginseng are removed by filtration, and water is evaporated under reduced pressure so that the extract is 3000 g or less to obtain a saponin composition containing saponin compounds of formula (I). Got it.
제조예 2: 사포닌 조성액Preparation Example 2: Saponin Composition
직전 사포닌 조성액의 제조과정으로부터의 잔여액에 30분 함침한 후 꺼내어, 2일 동안 30℃의 온도에서 숙성하여 전처리한 인삼 250g을, 벌꿀 50g, 포도당 50g, 물엿 50g으로 이루어진 혼합물 150g, 생지황 10g, 감초 10g, 대추 5g으로 이루어진 식용 감미건약제 25g, 사과식초 10g, 현미식초 10g, 모과 5g의 식용 유기산 건약제 25g, 죽염 5g, 반응촉매로서 은의 분말 0.01g 및 펠렛 9.99g 및 물 3000g과 함께 환류장치가 부착된 추출 반응기에 선별적으로 투입하고, 상압하에서 약 120℃에서 50시간 동안 반응시켜 추출한 후, 인삼 등 고형물들을 여과하여 제거하고, 추출액이 2500g이하가 되도록 감압하에 수분을 증발시켜 화학식Ⅰ의 사포닌 화합물들을 포함하는 사포닌 조성액을 얻었다.After impregnating the remaining solution from the preparation of the saponin composition solution for 30 minutes, taken out, aged 250 g of pretreated ginseng at 30 ° C. for 2 days, 150 g of honey, 50 g of glucose, 50 g of starch syrup, 10 g of raw sulfur, 25g of edible sweetener with 10g of licorice, 5g of jujube, 10g of apple vinegar, 10g of brown rice vinegar, 25g of edible organic acid medicinal agent of 5g of quince, 5g of bamboo salt, 0.01g of silver powder and 9.99g of pellets and 3000g of water as reaction catalyst Selectively added to the extraction reactor attached to the device, the reaction was extracted by reaction at about 120 ℃ at 50 ℃ for 50 hours, and then filtered to remove solids such as ginseng, and evaporated the water under reduced pressure so that the extract is less than 2500g formula (I) A saponin composition containing saponin compounds was obtained.
제조예 3: 사포닌 조성액Preparation Example 3 Saponin Composition
직전 사포닌 조성액의 제조과정으로부터의 잔여액에 20분 함침한 후 꺼내어, 5일 동안 27℃의 온도에서 숙성하여 전처리한 인삼 200g을, 벌꿀 100g, 흑설탕 50g, 물엿 50g의 혼합물 200g, 대추 10g, 감초 5g으로 이루어진 식용 감미건약제 15g, 모과 10g과 감식초 15g으로 이루어진 식용 유기산 건약제 25g, 죽염 10g, 반응형 촉매로서 맥반석 15g과 금 펠렛 2g 및 물 3000g과 함께 환류장치가 부착된 추출 반응기에 선별적으로 투입하고, 상압하에서 약 120℃에서 70시간 동안 반응시켜 추출한 후, 인삼 등 고형물들을 여과하여 제거하고, 추출액이 2000g 이하가 되도록 감압하에 수분을 증발시켜 화학식Ⅰ의 사포닌 화합물들을 포함하는 사포닌 조성액을 얻었다.Immediately after the impregnation of the saponin composition solution for 20 minutes, it was taken out, and then taken out and aged for 5 days at a temperature of 27 ° C., 200 g of honey, 100 g of honey, 50 g of brown sugar, 200 g of starch syrup, 10 g of jujube, licorice 15 g of edible sweetener of 5g, 25g of edible organic acid of 10g of quince and 15g of vinegar, 10g of bamboo salt, 15g of ganbanite, 2g of gold pellets and 3000g of water as a reactive catalyst, selectively in an extraction reactor equipped with a reflux device And extracted by reacting for about 70 hours at 120 ° C. under normal pressure, and then filtering and removing solids such as ginseng, and evaporating water under reduced pressure to obtain an extract of 2000 g or less to obtain a saponin composition containing saponin compounds of formula (I). Got it.
제조예 4: 사포닌 조성액Preparation Example 4 Saponin Composition
직전 사포닌 조성액의 제조과정으로부터의 잔여액에 40분 함침한 후 꺼내어, 10일 동안 25℃의 온도에서 숙성하여 전처리한 인삼 300g을, 벌꿀 80g, 포도당 10g, 물엿 10g으로 이루어진 혼합물 100g, 대추 20g, 숙지황 10g, 감초 5g, 곳감 5g으로 이루어진 식용 감미건약제 40g, 매실 19g, 구연산 1g으로 이루어진 식용 유기산 건약제 20g, 죽염 1.5g, 반응촉매로서 맥반석 19g과 백금사 1g 및 물 3000g과 함께 환류장치가 부착된 추출 반응기에 선별적으로 투입하고, 상압하에서 약 120℃에서 40시간 동안 반응시켜 추출한 후, 인삼 등 고형물들을 여과하여 제거하고, 추출액이 1500g 이하가 되도록 감압하에 수분을 증발시켜 화학식Ⅰ의 사포닌 화합물들을 포함하는 사포닌 조성액을 얻었다.Immediately after the impregnation of the remaining saponin composition solution for 40 minutes, taken out, aged for 30 days at 25 ° C., 300 g of pretreated ginseng, 80 g of honey, 10 g of glucose, 10 g of starch syrup, 100 g of jujube, Edible sweetener, 40g, composed of 10g of Sookjihwang, 5g of licorice, 5g of persimmon, 20g of edible organic acid, consisting of 19g of plum, 1g of citric acid, 1.5g of bamboo salt, 19g of ganban stone, 1g of platinum sand and 3000g of water as reaction catalyst Selectively added to the attached extraction reactor, extracted by reacting for 40 hours at about 120 ℃ under atmospheric pressure, and then removed by filtering solids such as ginseng, and evaporated the water under reduced pressure so that the extract is 1500g or less saponin of formula (I) A saponin composition containing compounds was obtained.
제조예 5: 사포닌 조성액Preparation Example 5 Saponin Composition
직전 사포닌 조성액의 제조과정으로부터의 잔여액에 15분 함침한 후 꺼내어, 1일 동안 32℃의 온도에서 숙성하여 전처리한 인삼 350g을, 벌꿀 100g과 물엿 50g의 혼합물 150g, 대추 25g, 감초 2g, 숙지황 3g으로 이루어진 식용 감미건약제 30g, 매실 20g, 모과 10g, 사과식초 5g, 현미식초 5g으로 이루어진 식용 유기산 건약제 40g, 죽염 2g, 반응촉매로서 은 펠렛 5g과 맥반석 25g, 및 물 3000g과 함께 환류장치가 부착된 추출 반응기에 선별적으로 투입하고, 상압하에서 약 120℃에서 70시간 동안 반응시켜 추출한 후, 인삼 등 고형물들을 여과하여 제거하고, 추출액이 3000g 이하가 되도록 감압하에 수분을 증발시켜 화학식Ⅰ의 사포닌 화합물들을 포함하는 사포닌 조성액을 얻었다.After impregnating the remaining solution from the preparation of the saponin composition solution for 15 minutes and taking out, 350 g of pretreated ginseng aged at 32 ° C. for 1 day, 150 g of a mixture of 100 g of honey and 50 g of starch syrup, 25 g of jujube, 2 g of licorice, and sorghum 30g of edible sweetener composed of 3g, 20g of plum, 10g of quince, 5g of apple vinegar, 40g of edible organic acid medicinal agent consisting of 5g of brown rice vinegar, 2g of bamboo salt, 5g of silver pellet, 25g of ganban stone, and 3000g of water as a reaction catalyst Was selectively added to the extraction reactor to which the reaction mixture was attached, and extracted by reacting for about 70 hours at about 120 ° C. under normal pressure, and then filtering and removing solids such as ginseng, and evaporating water under reduced pressure so that the extract was 3000 g or less. A saponin composition solution containing saponin compounds was obtained.
제조예 6: 화장품Preparation Example 6 Cosmetics
상기 실시예Ⅰ의 사포닌 조성액을 사용하여 다음 조성으로 이루어진 스킨을 제조하였다:Using the saponin composition of Example I was prepared a skin consisting of the following composition:
사포닌 조성액 60 중량%60% by weight of saponin composition
주정(식용 에틸알콜) 20 중량%20% by weight alcohol (edible ethyl alcohol)
알로에 추출물과 영지추출물 5 중량%5% by weight of aloe extract and ganoderma lucidum extract
쟈스민향 0.05중량%Jasmine 0.05% by weight
심해상어 간유와 이란산 캐비어 1 중량%Deep Sea Shark Liver Oil and Iranian Caviar 1% by weight
물 13.95중량%13.95% by weight of water
제조예 7: 화장품Preparation Example 7: Cosmetics
상기 실시예 1의 사포닌 조성액을 사용하여 다음 조성으로 이루어진 로션을 제조하였다:Using the saponin composition of Example 1 was prepared a lotion consisting of the following composition:
사포닌 조성액 70 중량%Saponin composition 70% by weight
꿀벌의 집 왁스 3 중량%
파라핀 오일 10 중량%10% by weight paraffin oil
팔미틴산 나트륨 0.5 중량%0.5% by weight sodium palmitate
오이, 수세미외, 동충하초 추출물 7 중량%Cucumber, loofah, Cordyceps sinensis extract 7% by weight
로즈향 0.03 중량%Rose flavor 0.03 wt%
심해상어 간유와 이란산 캐비어 1 중량%Deep Sea Shark Liver Oil and Iranian Caviar 1% by weight
물 8.47 중량%8.47% by weight of water
실험예 1. 함량분석 실험Experimental Example 1. Content Analysis Experiment
상기 제조예 1에서 제조한 사포닌 조성액의 함량분석을 위해 시료 100mg을 40% 아세토니트릴 10ml에 녹여(10000ppm) 0.2 ㎛의 멤브레인 필터로 여과한 후 칼럼에 주입하고 HPLC를 이용하여 측정하였다.In order to analyze the content of the saponin composition prepared in Preparation Example 1, 100 mg of the sample was dissolved in 10 ml of 40% acetonitrile (10000 ppm), filtered through a 0.2 μm membrane filter, injected into a column, and measured by HPLC.
비교를 위해 금산인삼조합의 홍삼액 및 정관장 홍삼액 (KT&G사 제품) 의 함량분석을 동일한 조건하에서 실시하였다. 그 결과를 도 1 내지 도 3에 나타내었다.For comparison, the content analysis of red ginseng solution and Jeonggwanjang red ginseng solution (product of KT & G Co., Ltd.) of Geumsan ginseng combination was performed under the same conditions. The results are shown in FIGS. 1 to 3.
[측정조건][Measuring conditions]
칼럼: μ-Bondapak C18Column: μ-Bondapak C18
용매: A=H2 O, B=아세토니트릴Solvent: A = H 2 O, B = acetonitrile
0분 (B 17%); 10분 (B 33%); 88분 (B 60%); 100분(80%)0 min (
102분(B 17%); 110분(B 17%)102 minutes (
유속: 1ml/분Flow rate: 1ml / min
도 1 내지 도 3에서 가로축은 시간 (단위: 분)이며, 세로축은 진압(단위 mV)이다.1 to 3, the horizontal axis represents time (unit: minutes) and the vertical axis represents suppression (unit mV).
도 1의 그래프에서 볼 수 있듯이, 0.777분에서 3분 사이에 기존의 홍삼과 완전히 다른 피크(물질 1)를 보였다. 또한, 27.647분을 전후하여 약 7분 사이에서는 기존 홍삼에서 전혀 볼 수 없는 피크(물질 2)를 보였으며, 70분과 110분 사이에서는 기존의 홍삼에서 전혀 볼 수 없는 완만한 굴곡의 피크(물질 3)를 보였다. 따라서, 물질 1 내지 3은 본 발명의 제조방법에 따라 얻어진 신물질이라고 판단된다.As can be seen in the graph of Figure 1, between 0.777 to 3 minutes showed a completely different peak (material 1) from the existing red ginseng. In addition, between about 7 minutes before and after 27.647 minutes, the peak (Material 2) was not seen in the existing red ginseng. ) Accordingly, the substances 1 to 3 are judged to be new substances obtained according to the production method of the present invention.
또한, 물질 1의 영역에서 기존의 홍삼 피크는 대부분 7이하로 알려져 있으나, 본 발명의 피크는 9mV이상이었다. 물질 2의 피크는 기존의 홍삼에서는 볼 수 없으며 2.5 mV의 완만한 피크를 보였다. 또한, 물질 3의 영역에서, 기존의 홍삼에서는 날카로운 5mV 높이의 여러 개의 피크가 나타내지만, 본 발명의 피크는 100분을 전후하여 완만한 피크를 이루는 새로운 피크가 나타났으며, 이것은 본 발명에서 얻어진 신물질을 나타내는 것이라 판단된다.In addition, although the existing red ginseng peak in the region of substance 1 is known to be 7 or less, the peak of the present invention was 9 mV or more. The peak of
도 1 및 도 2의 결과를 하기 표 1 ~ 2에 나타내었다. 또한, 표 1을 이용하여 본원 발명의 사포닌 함량을 측정하였고, 그 결과를 하기 표 3에 나타내었다.The results of FIGS. 1 and 2 are shown in Tables 1 and 2 below. In addition, the saponin content of the present invention was measured using Table 1, and the results are shown in Table 3 below.
표 1.Table 1.
표 2.Table 2.
표 3.Table 3.
상기 제조예 1 ∼ 7에서 제조한 사포닌 조성액 및 화장품을 사용하여 다음과 같은 임상실험을 실시하였다.The following clinical experiments were carried out using the saponin composition and cosmetics prepared in Preparation Examples 1 to 7.
임상예 1Clinical example 1
나이: 만 55세 (남)Age: 55 (M)
증세: 손 습진, 발 무좀Symptoms: hand eczema, foot athletes foot
결과: 제조예 1에 따른 사포닌 조성액 0.5 ∼ 1 g을 각각 손과 발의 습진 및 무좀 부위에 1일 3회씩 3 ∼ 10일 정도 바른 결과, 피부가 부드러워지고 윤기가 나며 상기 병증이 완전히 없어졌다.RESULTS: 0.5 to 1 g of saponin composition according to Preparation Example 1 was applied to the eczema and athlete's foot of the hand and foot three times a day for 3 to 10 days, respectively, resulting in a smooth, shiny and completely disappeared condition.
임상예 2Clinical example 2
나이: 만 55세 (남)Age: 55 (M)
증세: 숙취Symptoms: Hangover
결과: 인사불성 상태의 과음 후, 제조예 2에 따른 사포닌 조성액을 20 ∼ 30 cc씩 아침 저녁으로 물 1컵에 희석하여 복용하였다. 인사불성 상태의 과음은 소화기관, 간장, 심장, 폐 등에 심각한 해를 끼치는데, 상기 혼합액을 복용 후 1 ∼ 2일만에 숙취해소의 원상태로 회복되었고, 과음시 입술이 암갈색으로 변하였으나, 혼합액 복용 2∼ 3일 후 선홍색의 원상태로 회복하였다.RESULTS: After excessive drinking in a state of insomnia, the saponin composition according to Preparation Example 2 was taken by diluting 20 to 30 cc each morning and evening in 1 cup of water. Drinking in a state of aggravation causes serious harm to the digestive organs, liver, heart, lungs, etc. After taking the mixed solution, the hangover was restored to its original state within 1 to 2 days. After 2-3 days, it returned to its original state of bright red.
임상예 3Clinical example 3
나이: 만 18세 (남)Age: 18 years old (male)
증세: 만성피로, 유난히 검은 피부Symptoms: Chronic Fatigue, Exceptionally Dark Skin
결과: 제조예 3에 따른 사포닌 조성액을 1일 2회, 1회 20cc씩의 양으로 90일 복용 후, 원기가 회복되고 피로가 해소되었으며 집중력이 좋아졌다. 또한, 유난히 검고 거친 피부가 희고 부드러워졌다.RESULTS: After taking 90 days of saponin composition solution according to Preparation Example 2 twice daily, 20 cc each, refreshment, fatigue was relieved and concentration was improved. In addition, exceptionally black and rough skin became white and soft.
임상예 4Clinical example 4
나이: 만 41세 (여)Age: 41 years old
증세; 만성피로, 우울증, 검은 피부Symptoms; Chronic fatigue, depression, dark skin
결과: 제조예 4에 따른 사포닌 조성액 20 ∼ 30 cc를 물 1컵에 희석하여 1일 1 ∼ 2회 100일 복용한 결과, 우울증 상태가 없어져가고, 원기회복되어 피로가 회복되었으며, 검은 황색피부가 희고 부드러우며 윤기가 생겼다.Results: 20 to 30 cc of saponin composition according to Preparation Example 4 was diluted in 1 cup of water and then taken once or twice a day for 100 days. The state of depression disappeared, rejuvenated and fatigue was recovered. It is white, soft and shiny.
임상예 5Clinical example 5
나이: 6세 (여)Age: 6 years old
증세: 폐렴 증세, 면역력 약화Symptoms: pneumonia, weakened immunity
결과: 제조예 5에 따른 사포닌 조성액을 5cc의 양으로 1일 2회 2주 복용한 결과, 폐렴 증세가 완치되고, 원기회복되며 면역력이 강화되었다.Results: When saponin composition according to Preparation Example 5 was taken twice a day for 2 weeks in an amount of 5 cc, pneumonia was cured, rejuvenated, and immunity was enhanced.
임상예 6Clinical example 6
나이: 36세 (여)Age: 36 years old
증세: 알러지성 비염Symptoms: Allergic Rhinitis
결과: 제조예 1에 따른 사포닌 조성액을 20cc의 양으로 1일 2회 30일 복용한 결과, 원기회복되고 면역력이 강화되어 비염 증상이 없어졌다.RESULTS: When saponin composition according to Preparation Example 1 was taken twice a day for 30 days in an amount of 20 cc, it rejuvenated and the immunity was strengthened so that rhinitis symptoms disappeared.
임상예 7Clinical example 7
나이: 만 38세 (남)Age: 38 (Male)
증세: 면역력 약화로 감기 및 합병증이 지속됨Symptoms: Colds and complications persist due to weakened immunity
결과: 제조예 2에 따른 사포닌 조성액을 20cc의 양으로 1일 1회 60일 복용한 결과, 면역력이 강화되고 및 원기가 회복되어 감기에 걸리지 않고 합병증도 해소되었다.RESULTS: When saponin composition according to Preparation Example 2 was taken once daily for 60 days in an amount of 20 cc, immunity was strengthened and rejuvenated to prevent colds and complications were eliminated.
임상예 8Clinical Example 8
나이: 54세 (남)Age: 54 years old (male)
증세: 위암절제 후 회복기Symptoms: Recovery from stomach cancer
결과: 제조예 3에 따른 사포닌 조성액을 30cc의 양으로 1일 2회 45일 복용한 결과, 단백질 생성이 강화되어 정상적 생활을 유지할 수 있게 되었고, 수술 후유증으로 땀흘림 증세가 심했으나, 원기회복으로 정상으로 회복되었다.Results: After taking saponin composition according to Preparation Example 3 twice a day for 45 days in 30cc, protein production was strengthened to maintain a normal life. It returned to normal.
임상예 9Clinical Example 9
나이: 20세 (남)Age: 20 years old (male)
증세: 축농증, 잦은 감기Symptoms: sinusitis, frequent colds
결과: 제조예 4에 따른 사포닌 조성액을 20cc의 양으로 1일 1회 110일 복용한 결과, 면역강화로 축농증이 치유되었고 잦은 감기가 없어졌다. 또한, 정신이 맑아지고 집중력 향상되었다.RESULTS: The saponin composition according to Preparation Example 4 was taken once daily for 110 days in an amount of 20 cc. As a result, sinusitis was cured by immune strengthening and frequent colds disappeared. It also cleared my mind and improved my concentration.
임상예 10Clinical Example 10
나이: 50세 (여)Age: 50 years old (Female)
증세: 혈액순환 장해로 인한 하체 부종 및 당뇨 증세Symptoms: Lower body edema and diabetes due to blood circulation disorders
결과: 제조예 5에 따른 사포닌 조성액을 30cc의 양으로 1일 1회 90일 복용한 결과, 부종이 없어지고 원기 회복 및 면역강화로 당뇨성 피로와 기타 합병증이 없어졌다.Results: When saponin composition according to Preparation Example 5 was taken once a day for 90 days in an amount of 30 cc, edema was eliminated and diabetic fatigue and other complications were eliminated due to rejuvenation and immune strengthening.
임상예 11Clinical Example 11
나이: 60세 (여)Age: 60 years old (Female)
증세: 검고 거친 피부, 다리의 근력부족으로 오르막길 오르기에 심한 피로감, 잦은 감기.Symptoms: dark, rough skin, severe fatigue to climb uphill due to lack of muscle strength in the legs, frequent colds.
결과: 제조예 1에 따른 사포닌 조성액을 25cc의 양으로 1일 1회 60일 복용한 결과, 피로감이 없어지고 면역강화로 다리의 단백질 생성이 강화되었고, 잦은 감기가 없어졌다. 피부가 희어지고 탄력이 생겨 윤기가 났다.Results: When the saponin composition according to Preparation Example 1 was taken once daily for 25 days in an amount of 25cc, fatigue was eliminated, and protein production of the leg was enhanced by immune strengthening, and frequent colds were eliminated. The skin became white and elastic and shiny.
임상예 12Clinical Example 12
나이: 72세 (여)Age: 72 years old (Female)
증세: 당뇨, 감기 및 세균성 합병질환Symptoms: diabetes, cold, and bacterial complications
결과: 제조예 2에 따른 사포닌 조성액을 25cc의 양으로 1일 2회 40일 복용한 결과, 세균성 질환에 대한 면역강화 및 원기회복으로 합병질환이 없어졌고, 당질 대사의 강화로 당 수치가 현저히 감소되었다.RESULTS: When saponin composition according to Preparation Example 2 was taken twice a day for 40 days in an amount of 25cc, complications were eliminated due to enhanced immunity to bacterial diseases and rejuvenation. It became.
임상예 13Clinical Example 13
일반화장품을 사용할 수 없는 정도의 과민성 피부를 가진 22 ∼ 42세의 여성 7명에게 제조예 6 및 7에 따른 스킨과 로션을 1일 3회씩 1주일 이상 지속적으로 사용하게 한 결과, 과민반응 및 피부 트러블이 전혀 일어나지 않았다.Sensitization and skin sensitization resulted from seven women aged 22 to 42 who had irritable skin that could not use general cosmetics. Trouble did not occur at all.
본 발명에 따른 사포닌 화합물 또는 이것을 함유하는 사포닌 조성액을 활성 성분으로 포함하는 약제학적 조성물 및 기능성 식품은 면역증강, 체력증강, 간기능 보호 및 숙취해독, 단백질 생성 촉진, 두뇌활동 촉진 및 집중력 향상 및 수술후 회복증강 작용을 할뿐 아니라, 당뇨병, 혈액순환장해, 우울증, 피부질환, 무좀, 습진, 알레르기 비염, 축농증 등의 질환의 예방 또는 치료 효과를 갖는다. 본 발명에 따른 사포닌 화합물 또는 이것을 함유하는 사포닌 조성액을 활성성분으로 포함하는 화장품은 민감성 피부를 갖는 사람도 적합하게 사용할 수 있다.Pharmaceutical compositions and functional foods comprising a saponin compound or a saponin composition containing the same according to the present invention as an active ingredient, immune enhancement, physical strength enhancement, liver function protection and hangover detoxification, protein production, brain activity promotion and concentration enhancement and postoperative In addition to the restorative action, it has the effect of preventing or treating diseases such as diabetes, blood circulation disorders, depression, skin diseases, athlete's foot, eczema, allergic rhinitis, sinusitis. Cosmetics containing the saponin compound according to the present invention or a saponin composition containing the same as an active ingredient can be suitably used even by a person having sensitive skin.
Claims (11)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030039622 | 2003-06-19 | ||
KR20030039622 | 2003-06-19 | ||
KR20030053378 | 2003-08-01 | ||
KR1020030053378 | 2003-08-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060038396A true KR20060038396A (en) | 2006-05-03 |
KR100746799B1 KR100746799B1 (en) | 2007-08-23 |
Family
ID=33554578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057024035A KR100746799B1 (en) | 2003-06-19 | 2004-06-18 | A preparation method of new saponin solution |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100746799B1 (en) |
WO (1) | WO2004111069A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101106499B1 (en) * | 2009-03-24 | 2012-01-20 | 장흥군 | Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb |
KR101155967B1 (en) * | 2009-09-11 | 2012-06-18 | 김달수 | A health food composition for prevention and treatment of allergic rhinitis containing Germanium, elvan and red ginseng Extracts |
KR20130035324A (en) * | 2011-09-30 | 2013-04-09 | (주)아모레퍼시픽 | Surfactant containing saponin extracted from the root of camellia sinensis and liquid cleansing composition comprising the same |
KR101380556B1 (en) * | 2012-04-26 | 2014-04-01 | 합자회사 에스에이치해양수산개발 | Soap composition comprising salt having saponin from sea slug and preparation method thereof |
KR20180038144A (en) * | 2016-10-06 | 2018-04-16 | 농업회사법인 월파 주식회사 | Ginseng Sikhye manufacturing method for rice production method and Bob Sikhye |
KR102247551B1 (en) * | 2020-12-31 | 2021-05-03 | 주식회사 네이처프롬 | A cream that can relieve swelling by using ginseng water and a method of manufacturing it |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006223140A (en) * | 2005-02-16 | 2006-08-31 | Kiyoshi Sato | Dietary supplement |
US7981308B2 (en) | 2007-12-31 | 2011-07-19 | Robert Bosch Gmbh | Method of etching a device using a hard mask and etch stop layer |
GB2455585B (en) * | 2008-01-16 | 2010-07-28 | Ali Reza Rezai-Fard | Capsicum seeds for the treatment of eczema and dermatitis |
CN103613680B (en) * | 2013-12-05 | 2016-06-01 | 三峡大学 | Alcohol-precipitated panax japonicus polysaccharide, preparation method and application thereof |
CN104383028A (en) * | 2014-10-30 | 2015-03-04 | 洛阳蓝斯利科技有限公司 | Method for preparing liquorice foot bath powder |
CN114957495A (en) * | 2022-01-04 | 2022-08-30 | 北华大学 | Schisandra chinensis plant polysaccharide and preparation method and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930005989B1 (en) * | 1991-01-22 | 1993-07-01 | 주식회사 대웅제약 | Preparation of |3-0-(2',3',4',6'-tetra-0-acetyl-beta-d-glucopyranosyl)-20(s)-protopanaxadiol¨ |
KR0169536B1 (en) * | 1996-02-27 | 1999-01-15 | 손경식 | Novel ginseng saponins, process for preparation thereof and anti-tumor agents containing the same as an active ingredient |
-
2004
- 2004-06-18 WO PCT/KR2004/001459 patent/WO2004111069A2/en active Application Filing
- 2004-06-18 KR KR1020057024035A patent/KR100746799B1/en not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101106499B1 (en) * | 2009-03-24 | 2012-01-20 | 장흥군 | Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb |
KR101155967B1 (en) * | 2009-09-11 | 2012-06-18 | 김달수 | A health food composition for prevention and treatment of allergic rhinitis containing Germanium, elvan and red ginseng Extracts |
KR20130035324A (en) * | 2011-09-30 | 2013-04-09 | (주)아모레퍼시픽 | Surfactant containing saponin extracted from the root of camellia sinensis and liquid cleansing composition comprising the same |
KR101380556B1 (en) * | 2012-04-26 | 2014-04-01 | 합자회사 에스에이치해양수산개발 | Soap composition comprising salt having saponin from sea slug and preparation method thereof |
KR20180038144A (en) * | 2016-10-06 | 2018-04-16 | 농업회사법인 월파 주식회사 | Ginseng Sikhye manufacturing method for rice production method and Bob Sikhye |
KR102247551B1 (en) * | 2020-12-31 | 2021-05-03 | 주식회사 네이처프롬 | A cream that can relieve swelling by using ginseng water and a method of manufacturing it |
Also Published As
Publication number | Publication date |
---|---|
KR100746799B1 (en) | 2007-08-23 |
WO2004111069A2 (en) | 2004-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100534474C (en) | Medicine composition for enhancing immunity, and its preparation method and use | |
KR100746799B1 (en) | A preparation method of new saponin solution | |
JP4777776B2 (en) | Ginseng preparation using vinegar and method for producing the same | |
KR100228510B1 (en) | A process for the preparation of ginsenoside Rg3 and/or Rg5 | |
AU2008215743B2 (en) | A composition for selective serotonin reuptake inhibition and process thereof | |
CN110354204B (en) | Composition with eyesight improving effect and preparation and application methods thereof | |
CN110559332A (en) | Ganoderma lucidum and grifola frondosa hypoglycemic composition as well as preparation method and application thereof | |
CN106420886A (en) | Composition with physical fatigue alleviating and immunity enhancing functions, and preparation method thereof | |
CN1879656B (en) | Solid water soluble propolis composition and preparation method thereof | |
CN112546167A (en) | Traditional Chinese medicine composition with spleen invigorating and dampness removing functions and preparation method and application thereof | |
CN103564495B (en) | Propolis and cordycepic hypha powder composition, as well as preparation and application thereof | |
CN107751993A (en) | A kind of antifatigue cream taste and preparation method thereof | |
KR100635025B1 (en) | A ginseng preparation using vinegar and process for thereof | |
CN104666643B (en) | A kind of compound snow chrysanthemum product and its preparation method and application | |
JP2008231031A (en) | Dehydroepiandrosterone production promoter and use thereof | |
CN104606451B (en) | A kind of medicine-food dual-purpose composition and preparation method for reducing postprandial blood sugar (IGT states) | |
KR101416671B1 (en) | Ginseng prosapogenin high concentration containing ginseng leaf or stem preparation using sonication and process for thereof | |
CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
CN102558128B (en) | Preparation method of extract containing prodelphinidin and procyanidin of ginkgo | |
CN107233488A (en) | A kind of Chinese medicine composition for delaying cell and vascular ageing | |
CN1557840A (en) | Polysaccharides compound preparation and method for preparing the same | |
KR101738206B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
KR101520630B1 (en) | Shampoo and essence using cosmetic composition for preventing loss of hair containing nine times-steaming ginseng extract and natural oriental medicine extracts | |
CN112076292A (en) | Powder with functions of enhancing immunity and regulating kidney yin deficiency and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120816 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130829 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140814 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |